Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

145 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-18

Study Completion Date

2022-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, randomized, controlled, multicenter, international clinical trial. The study population consist of patients with paroxysmal or persistent atrial fibrillation with out range hypertension or signs of sympathetic overdrive. Patient will be randomized into one of the following two groups.

group 1 : patients will undergo pulmonary vein isolation, group 2: Patients will undergo pulmonary vein isolation and renal artery denervation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Characterization of the Mechanisms of Atrial Fibrillation Maintenance

NCT02497248

Atrial Fibrillation

COMPLETED

Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation

NCT02071511

Ventricular Tachycardia Cardiomyopathy

TERMINATED NA

Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter

NCT01710150

Typical Atrial Flutter Risk Factors With Future Development of Atrial Flutter

WITHDRAWN NA

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

NCT02064764

Atrial Fibrillation Hypertension

COMPLETED NA

Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins

NCT00605748

Atrial Fibrillation

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The target group of patients are subjects ages \<65 years, with paroxysmal or persistent atrial fibrillation, who have out of range hypertension (systolic \>140 mmHg or \>130/80 mmHg in diabetics and patients with chronic renal disease) or signs of sympathetic overdrive. Patients should use at least 2 anti-hypertensive's or should be intolerant for antihypertensive medication.

Atrial fibrillation terminology: If atrial fibrillation recurs more than once but terminates spontaneously within seven days, the term paroxysmal AF is used. This is also used when the episode is less than 48 hours in duration and is terminated with electrical or pharmacological cardioversion. Persistent AF is defined as recurrent AF that is sustained for more than seven days. A patient that is electrically or pharmacologically cardioverted after more than two days is also diagnosed with persistent AF.

After the exclusion of apparent secondary causes of hypertension, patients will be randomized to one of the following interventional treatments:

First arm: PVI (69 patients) Second arm: PVI + RDN (69 patients)

The patient will be treated under conscious sedation or general anesthesia. The control group will consist of patients who undergo PVI alone. The study will be a randomized, controlled trial. The follow up period will be up to one year after the interventional therapy. Patients will be treated clinically and will have regular follow-up at the outpatient clinic of the hospital at which they were treated. If patients receive continuous loop recorders for cardiac rhythm monitoring, this data will be used for the study. The other patients will undergo Holter ECG monitoring at regular intervals during follow-up (at 3, 6 and 12 months after the interventional treatment). During follow-up, the first 3 months after the interventional treatment will be a blanking period, as is common in the ablative therapy of AF (ablations points need to heal, and paroxysms of AF in this period are not associated with therapy failure).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation Out of Range Hypertension Signs of Sympathetic Overdrive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pulmonary vein+renal artery denervation

Procedure: pulmonary vein and renal artery denervation

Group Type ACTIVE_COMPARATOR

procedure

Intervention Type PROCEDURE

Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

Pulmonary vein isolation

Procedure: Pulmonary vein isolation

Group Type ACTIVE_COMPARATOR

procedure

Intervention Type PROCEDURE

Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

procedure

Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient is willing and able to comply with the protocol and has provided written informed consent.
2. The patient falls within the target group resistant hypertension or sympathetic overdrive
3. Patient is an acceptable candidate for renal denervation treatment
4. Patient is \< 65 year of age

Exclusion Criteria

1. Documented left atrial diameter on trans thoracic echocardiography (PLAX \> 4.5 cm).
2. Contraindication to chronic anticoagulation therapy or heparin.
3. Previous left heart ablation procedure for AF (atrial fibrillation).
4. Acute coronary syndrome, cardiac surgery, PCI (percutaneous coronary intervention)or stroke within 3 months prior to enrollment.
5. Untreated hypothyroidism or hyperthyroidism.
6. More than grade 1/3 valvular regurgitation and/or significant valve stenosis (modest or severe).
7. LVEF (Left ventricular function) \<45% and/or grade 3/4 diastolic dysfunction.
8. Enrollment in another investigational drug or device study.
9. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age.
10. Mental or physical inability to participate in the study.
11. Planned cardiovascular intervention.
12. Life expectancy ≤ 12 months.
13. Renal artery stenosis \>50% of the arterial lumen, or renal artery lumen

≤3 mm.
14. Dual or triple ipsilateral renal artery ostia.
15. Obvious secondary cause of hypertension.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No